India's Pharma Exports Surge to 4.96 Billion USD in April-May 2025

The Indian pharmaceutical industry achieved a worthwhile of 7.38 with April-May FY26, which recorded $4.961 billion in Indian pharmaceutical exports compared to the same period in FY25, showing a healthy growth rate, as reported by Pharmexcil. This boom highlights the emergence of India as a world leader in pharmaceutical market, that is commonly referred to as the Pharmacy of the World.

Pharmexcil, which is an authorised body under the Ministry of Commerce and Industry, cites strategic efforts aimed at moving towards sustainable production, enhanced international market share and digitalisation as responsible behind this growth. These endeavors are allied to the vision that India has to attain a trillion dollar trade mark in its pharmaceutical industry.

Drug formulations and biologicals took the frontline, constituting 75.74% of the exports. The bulk drugs and drug intermediates expanded at the rate of 4.4%, whereas the export volume of vaccines increased considerably by 13.64 percent to reach 190.13 million dollars. Other heavily imported products were surgical products and Ayush/herbal products, which recorded growths of 8.58 percent and 7.36 percent, respectively.

The US continues to be India’s best destination for export, and in May alone it received pharma export worth $1.7 billion, amounting to 34.5 percent of the total exports. The share of exports to NAFTA region, Europe, Africa and Latin America combined is 76 percent and ASEAN region has become the new growth region.

Namit Joshi, Pharmexcil Chairman, mentioned the increasing world demand, simplification of regulations, and technological changes as the significant ones. The continued discussions of India-UK Free Trade Agreement will likely further develop supply chains and investment in contract development and manufacturing.

Also Read: Lyfius Pharma Resumes Penicillin-G Production in Kakinada Plant

The pharmaceutical industry in India is a multibillion dollar industry with the sector currently standing at 50 billion in the FY23-24, expected to exceed 130 billion by 2030 making it a leading industry of generic medicines and vaccines across the world.